Safety profile of recombinant canarypox HIV vaccines

Vaccine

Volumn 22, Issue 5-6, 2004, Pages 704-713

  De Bruyn, Guy ^a   Rossini, Anthony J ^a   Chiu, Ya Lin ^a   Holman, Drienna ^a   Elizaga, Marnie L ^b   Frey, Sharon E ^c   Burke, Donald ^d   Evans, Thomas G ^e,f   Corey, Lawrence ^a   Keefer, Michael C ^e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f Vical   (United States)

Author keywords

Canarypox; Clinical trial; HIV; Reactogenicity; Safety; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN SUBUNIT; RECOMBINANT CANARYPOX VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; ERYTHEMA; FEMALE; FEVER; GENE CONSTRUCT; GENE INSERTION; HEADACHE; HISPANIC; HUMAN; HYPERTHERMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN INDURATION; STATISTICAL SIGNIFICANCE; VACCINATION; VIRUS INFECTION;

EID: 9144251565     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.08.023     Document Type: Article

References (25)

1. Shiver J.W., Fu T.M., Chen L.et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 415(6869):2002;331-335.
2. Musey L., Hughes J., Schacker T., Shea T., Corey L., McElrath M.J. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337(18):1997;1267- 1274.
3. Gupta K., Hudgens M., Corey L.et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS vaccine evaluation group protocol 022A. J. Acquir. Immune. Defic. Syndr. 29(3):2002;254-261.
4. The AIDS Vaccine Evaluation Group Protocol 022 Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 2001;183(4):563-70.
5. Ward B.J. Vaccine adverse events in the new millennium: is there reason for concern? Bull. World Health Organ. 78(2):2000;205-215.
6. Dittmann S. Vaccine safety: risk communication - a global perspective. Vaccine. 19(17-19):2001;2446-2456.
7. Breiman R.F., Zanca J.A. Of floors and ceilings: defining, assuring, and communicating vaccine safety. Am. J. Public Health. 87(12):1997;1919-1920.
8. Fries L.F., Tartaglia J., Taylor J.et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 14(5):1996;428-434.
9. Adler S.P., Plotkin S.A., Gonczol E.et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J. Infect. Dis. 180(3):1999;843-846.
10. Berencsi K., Gyulai Z., Gonczol E.et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J. Infect. Dis. 183(8):2001;1171-1179.
11. Keefer M.C., Wolff M., Gorse G.J.et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses. 13(14):1997;1163-1177.
12. Jackson L.A., Benson P., Sneller V.P.et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA. 281(3):1999;243-248.
13. Ponka A., Leinonen M. Adverse reactions to polyvalent pneumococcal vaccine. Scand. J. Infect. Dis. 14(1):1982;67-71.
14. Christy C., Pichichero M.E., Reed G.F.et al. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics. 96(3 Pt 2):1995;584-587.
15. Robb H., Fausone C.A., Rudy D.R., McArthur S. Side effects from influenza vaccination: differences between returned and random surveys. Mil. Med. 161(1):1996;29-32.
16. Govaert T.M., Dinant G.J., Aretz K., Masurel N., Sprenger M.J., Knottnerus J.A. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. Br. Med. J. 307(6910):1993;988-990.
17. Popejoy L.A., Rivera A.I., Gonzales-Torres I. Side-effects and immunogenicity of Haemophilus influenzae type B polysaccharide vaccine in a multiethnic pediatric population. Mil. Med. 154(1):1989;25-29.
18. Hilleman M.R., Carlson A.J. Jr., McLean A.A., Vella P.P., Weibel R.E., Woodhour A.F. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Rev. Infect. Dis. 3(Suppl):1981;S31-42.
19. Borgono J.M., McLean A.A., Vella P.P.et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc. Soc. Exp. Biol. Med. 157(1):1978;148-154.
20. Clements-Mann M.L., Weinhold K., Matthews T.J.et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177(5):1998;1230-1246.
21. Belshe R.B., Gorse G.J., Mulligan M.J.et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS. 12(18):1998;2407-2415.
22. Belshe R.B., Stevens C., Gorse G.J.et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis. 183(9):2001;1343-1352.
23. Evans T.G., Keefer M.C., Weinhold K.J.et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180(2):1999;290-298.
24. Evans T.G., Kallas E.G., Campbell M.et al. Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production. Immunol. Lett. 77(1):2001;7-15.
25. Cadoz M., Strady A., Meignier B.et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 339(8807):1992;1429-1432.